WARSAW, Poland, February 17, 2010 /PRNewswire-FirstCall/ --
- Addition of Polish Research Reactor Helps With Worldwide Supply Shortage
Covidien (NYSE: COV), a leading global provider of healthcare products, and the Institute of Atomic Energy in Poland (IAE POLATOM) today announced an agreement to augment and further diversify Covidien's supply of Molybdenum 99 (Mo 99) to produce the medical isotope Technetium 99m (Tc 99m).
Tc 99m is a vital medical isotope used in over 80 percent of all nuclear medicine diagnostic and functional studies of organs and anatomical systems. The information from these studies is used by many medical specialists (including radiologists, nephrologists, oncologists and cardiologists) to better diagnose and treat patients. More than 35 million nuclear medicine procedures are performed worldwide each year, more than half in the United States.
Adding the IAE POLATOM'S Maria Research Reactor to Covidien's global supply chain is expected to help Covidien meet the needs of more than one million additional patients in just the first six months after the reactor begins supplying Mo 99.
"This is an historic agreement. It is the first time in decades that a new reactor has been brought into the global supply chain for medical isotopes," said Timothy R. Wright, President, Pharmaceuticals, Covidien. "We are excited that we will now be working together to provide more than a million patients around the globe with access to a critical medical isotope during this serious shortage."
The announcement comes two days before the High Flux Reactor (HFR) in
Copyright©2010 PR Newswire.
All rights reserved